SecBot SecBot
SECBOTREPLAY Home › Report › BIIB

BIIB · LEQEMBI Pen launched in Japan

Biogen Inc.; Eisai Co., Ltd. · PRESS-RELEASE filed Nov 12, 2026 at 18:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 12, 2026 at 18:30 ET

Eisai and Biogen launched LEQEMBI Pen, the subcutaneous autoinjector formulation of lecanemab, in Japan following NHI Drug Price listing. This is the second country launch after the U.S., offering once-weekly self-administration to reduce clinic visit burden and healthcare resource use for Alzheimer's disease patients.

  • LEQEMBI Pen launched in Japan on Nov 12, 2026, after NHI Drug Price listing at 27,141 JPY per pen.
  • Japan is the second country after the U.S. to launch the subcutaneous formulation.
  • LEQEMBI Pen is an autoinjector for once-weekly self-administration (500 mg total via two pens).
  • SC formulation showed similar exposure to IV and lower injection-related reaction incidence (1.4% vs IV).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access